

FOI REF: 23/872

15th January 2024

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500

Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

We are seeking to understand the initiation of patient treatment with Nivolumab and some additional products in different types of cancer. We would greatly appreciate if you could answer the following questions:

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

- **Ipilimumab (monotherapy)** 0
- **Nivolumab (monotherapy)** 0
- **Nivolumab AND Ipilimumab (combination)** 0
- **Pembrolizumab** 0
- **Any Targeted Therapy (Dabrafenib / Dabrafenib AND Trametinib / Encorafenib AND Binimetinib / Trametinib / Vemurafenib / Vemurafenib AND Cobimetinib)** 0
- **Other active systemic anti-cancer therapy** 0

* Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Please note that we do currently treat melanoma patients at East Sussex Healthcare NHS Trust.

Cont.../

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal cell carcinoma?

- **Nivolumab (monotherapy)** 1
- **Nivolumab + Ipilimumab** 0
- **Nivolumab + Cabozantinib** 0
- **Avelumab + Axitinib** 0

* **Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Q3 In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:

- **Nivolumab monotherapy or in combination with Ipilimumab** 0
- **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 3
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 2

* **Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Cont.../

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net